O-methyl-L-tyrosinamide | 7621-94-5

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: O-methyl-L-tyrosinamide
• 英文别名: Tyr(Me)-NH2；L-(4-methoxy)Phe-NH2；O-methyl-L-tyrosine amide；O-Methyl-L-tyrosin-amid；(S)-2-Amino-3-(4-methoxy-phenyl)-propionamide；L-4-methoxyphenylalaninamide；(2S)-2-amino-3-(4-methoxyphenyl)propanamide
• CAS: 7621-94-5
• 化学式: C₁₀H₁₄N₂O₂
• 分子量: 194.233
• InChiKey: SMVSJSSXYMNJBS-VIFPVBQESA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  14
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  78.3
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  O-methyl-L-tyrosinamide 在 三氟乙酸 作用下， 以 乙二醇二甲醚 为溶剂， 反应 1.0h， 生成 (S)-3-Amino-N-[(S)-1-carbamoyl-2-(4-methoxy-phenyl)-ethyl]-succinamic acid benzyl ester
  参考文献：
  名称：

  Development of Peptide 3D Structure Mimetics:  Rational Design of Novel Peptoid Cholecystokinin Receptor Antagonists

  摘要：

  The two hormones cholecystokinin and gastrin share the same C-terminal sequence of amino acids, namely Gly(29)-Trp(30)-Met(31)-Asp(32)-Phe(33)-NH2. Nevertheless, this congruence has not precluded using this structure to develop selective ligands for either CCK1 or CCK2 receptors. Manipulation of the hydrophobic residues at positions 31 and 33 gave a series of CCK1 tripeptide antagonists, typified by N-t-BOC-Trp-2-Nal-Asp-2-(phenyl)ethylamide (pK(B) 6.8 +/- 0.3). Molecular modeling was used to identify the bioactive conformation of these CCK1-selective compounds and prompted the design of new peptoid structures. We aimed to maintain the conformation of the parent series by exploiting patterns of hydrogen-bonding and pi-stacking interactions present in the original molecule, rather than introducing additional covalent bonds. The prototype, N-(succinyl-o-Asp-2-phenylethylamido)-L-Trp-2-( 2-naphthyl) ethylamide, was a potent and selective CCK1 antagonist (pK(B) 7.2 +/- 0.3). Furthermore, the new series showed patterns of biological activity that mirrored those of the parent tripeptides. These compounds contain elements of both peptide primary and secondary structure and represent a novel approach to designing peptidomimetics. Interesting results were obtained from comparing models of a representative tripeptide CCK1 antagonist with a conformation of CCK30-33 that others have proposed to be responsible for its activity at the CCK2 receptor. The results suggest that CCK1 and CCK2 receptors recognize enatiomeric dispositions of the Trp(30) indole, Asp(32) carboxylic acid, and C-terminal phenyl groups arrayed about a common backbone configuration. This "functional chirality" may underpin the mechanism by which these closely related receptor systems bind CCK30-33 and explain patterns of selectivity observed with optical isomers of a number of peptoid and nonpeptide ligands.

  DOI：

  10.1021/jm000937a
• 作为产物：
  描述：

  2-氨基-3-(4-甲氧基苯基)丙酸甲酯 在 ammonium hydroxide 作用下， 反应 10.0h， 生成 O-methyl-L-tyrosinamide
  参考文献：
  名称：

  使用铂和铋催化剂控制炔属酰胺的6-Exo和7-Endo环化

  摘要：

  环化规则：使用催化量的适当金属催化剂，将炔属酰胺区域选择性地环异构化为哌嗪-2-酮和1,4-二氮杂-2-酮衍生物。在Bi（OTf）3存在的情况下进行6- exo- dig加成，而对于同一底物，PtCl 2进行7- endo- dig加成。（参见方案; Ns =邻硝基苯磺酰基，Ts =对甲苯磺酰基，Cbz =苄氧羰基，DCE =二氯乙烷）

  DOI：

  10.1002/asia.201100209

文献信息

• Compositions for Treatment of Cystic Fibrosis and Other Chronic Diseases
  申请人：Vertex Pharmaceuticals Incorporated

  公开号：US20150231142A1

  公开（公告）日：2015-08-20

  The present invention relates to pharmaceutical compositions comprising an inhibitor of epithelial sodium channel activity in combination with at least one ABC Transporter modulator compound of Formula A, Formula B, Formula C, or Formula D. The invention also relates to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis using the pharmaceutical combination compositions.

  本发明涉及含有上皮钠通道活性抑制剂与至少一种ABC转运蛋白调节剂化合物（A式、B式、C式或D式）的药物组合物。该发明还涉及这些药物配方，以及使用这些组合物治疗CFTR介导的疾病，特别是囊性纤维化的方法。
• COMPOSITIONS FOR TREATMENT OF CYSTIC FIBROSIS AND OTHER CHRONIC DISEASES
  申请人：Van Goor Fredrick F.

  公开号：US20110098311A1

  公开（公告）日：2011-04-28

  The present invention relates to pharmaceutical compositions comprising an inhibitor of epithelial sodium channel activity in combination with at least one ABC Transporter modulator compound of Formula A, Formula B, Formula C, or Formula D. The invention also relates to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis using the pharmaceutical combination compositions.

  本发明涉及包含上皮钠通道活性抑制剂与至少一种ABC转运蛋白调节剂化合物（A式、B式、C式或D式）的药物组合物。该发明还涉及这些药物配方，以及使用这些组合物治疗CFTR介导的疾病，特别是囊性纤维化的方法。
• Mechanism of fluorescence quenching of tyrosine derivatives by amide group
  作者：Wiesław Wiczk、Alicja Rzeska、Joanna Łukomska、Krystyna Stachowiak、Jerzy Karolczak、Joanna Malicka、Leszek Łankiewicz

  DOI：10.1016/s0009-2614(01)00470-5

  日期：2001.6

  The difference between fluorescence lifetimes of the following amino acids: phenylalanine (Phe), tyrosine (Tyr), (O-methyl)tyrosine (Tyr(Me)), (3-hydroxy)tyrosine (Dopa), (3,4-dimethoxy)phenylalanine (Dopa(Me)2) and their amides was used to testify the mechanism of fluorescence quenching of aromatic amino acids by the amide group. On the basis of the Marcus theory of photoinduced electron transfer

  以下氨基酸的荧光寿命之间的差异：苯丙氨酸（Phe），酪氨酸（Tyr），（O-甲基）酪氨酸（Tyr（Me）），（3-羟基）酪氨酸（Dopa），（3,4-二甲氧基）苯丙氨酸（Dopa（Me）2）及其酰胺被用于证明酰胺基团对芳香族氨基酸进行荧光猝灭的机理。基于马库斯理论，得到了上述氨基酸的In k ET与因激发能而降低的电离电势之间的光诱导电子转移的抛物线关系。该发现表明发生了从激发的生色团基团到酰胺基团的光诱导电子转移。
• Organic Compounds
  申请人：BHALAY Gurdip

  公开号：US20100130506A1

  公开（公告）日：2010-05-27

  A compound of Formula I in free or salt or solvate form, where R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 and R 11 have the meanings as indicated in the specification, is useful for treating diseases which respond to the blockade of the epithelial sodium channel. Pharmaceutical compositions that contain the compounds and processes for preparing the compounds are also described.

  一种以自由形式、盐或溶剂形式存在的I式化合物，其中R1、R2、R3、R4、R5、R6、R7、R8、R9、R10和R11的含义如规范中所示，可用于治疗对上皮钠通道阻滞有反应的疾病。还描述了含有这些化合物的药物组合物以及制备这些化合物的方法。
• [EN] COMPOSITIONS FOR TREATMENT OF CYSTIC FIBROSIS AND OTHER CHRONIC DISEASES<br/>[FR] COMPOSITIONS DESTINÉES AU TRAITEMENT DE LA MUCOVISCIDOSE ET D'AUTRES MALADIES CHRONIQUES
  申请人：VERTEX PHARMA

  公开号：WO2011050325A1

  公开（公告）日：2011-04-28

  The present invention relates to pharmaceutical compositions comprising an inhibitor of epithelial sodium channel activity in combination with at least one compound of Formula I, Formula II, or Formula III. The invention also relates to solid forms and to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis using the pharmaceutical combination compositions.

  本发明涉及一种药物组合物，包括一种上皮钠通道活性抑制剂与至少一种公式I、公式II或公式III的化合物结合。本发明还涉及其固体形式和制药配方，以及使用这种组合物治疗CFTR介导疾病，尤其是囊性纤维化的方法。